What is Wixela? The Combination of Fluticasone and Salmeterol
Wixela Inhub is a prescription dry powder inhaler that delivers a combination of two active medications directly to the lungs: fluticasone propionate and salmeterol. Fluticasone propionate is a corticosteroid that reduces inflammation, while salmeterol is a long-acting bronchodilator that relaxes airway muscles. This combination provides comprehensive control of chronic respiratory conditions.
Approved Uses: For Maintenance Treatment of Asthma and COPD
Wixela is a maintenance medication for long-term use and is not for sudden breathing problems. Its approved uses include:
Asthma
For patients aged 4 years and older, Wixela is a twice-daily treatment for asthma not adequately controlled by other medications. It's also for patients who need both an inhaled corticosteroid and a LABA. Different strengths are available.
Chronic Obstructive Pulmonary Disease (COPD)
Adults with COPD can use Wixela twice daily for maintenance treatment of airflow obstruction. Specific strengths are indicated for reducing flare-ups in patients with a history of exacerbations. Some strengths may not offer additional benefits for COPD.
Important Safety Information and Potential Side Effects
Wixela has important safety considerations. The LABA component, when used alone for asthma, can increase the risk of asthma-related death and hospitalizations, but this risk is reduced in a combination product like Wixela.
Common Adverse Reactions (Incidence ≥ 3%)
- Upper respiratory tract infection or inflammation
- Sore throat (pharyngitis)
- Hoarseness (dysphonia)
- Oral candidiasis (thrush); rinsing mouth after use can help
- Headache
- Nausea and vomiting
- Pneumonia and viral respiratory infections in COPD patients
Serious Side Effects and Warnings
- Adrenal Suppression: May occur with long-term inhaled corticosteroid use.
- Paradoxical Bronchospasm: Sudden worsening of breathing, requiring immediate discontinuation and use of a rescue inhaler.
- Immunosuppression: Corticosteroids can increase susceptibility to infections.
- Cardiovascular Effects: Use with caution in patients with heart conditions.
- Bone Mineral Density: May decrease with long-term inhaled corticosteroid use.
- Eye Problems: Increased eye pressure, glaucoma, and cataracts can occur.
- Growth Effects: May reduce growth velocity in children.
Wixela Inhub vs. Other Inhalers
Wixela Inhub is the generic equivalent of Advair Diskus, containing the same active ingredients. They are considered therapeutically equivalent. For a detailed comparison of Wixela, Advair Diskus, and Advair HFA, including active ingredients, delivery system, approved use, device handling, and lactose content, please refer to DrOracle.ai.
How to Use Wixela Inhub Correctly
Correct technique ensures proper medication delivery. General steps include:
- Open the inhaler by pushing the yellow lever down until it clicks.
- Exhale fully away from the inhaler.
- Inhale quickly and deeply through the mouthpiece.
- Hold your breath for about 10 seconds.
- Exhale slowly.
- Close the mouthpiece cover.
- Rinse your mouth with water and spit it out to reduce the risk of thrush.
Use a rescue inhaler for sudden breathing problems, not Wixela.
Conclusion
Wixela is a combination inhaler for long-term asthma and COPD management, combining fluticasone and salmeterol to control symptoms and prevent exacerbations. As the generic equivalent to Advair Diskus, it offers a cost-effective alternative. It is intended for maintenance therapy only and not for acute symptom relief. Always consult a healthcare provider for guidance on use, potential side effects, and correct inhalation technique. Authoritative information can be found in the FDA prescribing information for Wixela Inhub DailyMed.
